60 stories tagged with #pharmaceuticals, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Pharmaceuticals"
Johnson & Johnson announces $7 billion settlement of talc lawsuits
The settlement covers claims alleging that J&J's talc products cause ovarian cancer. Read more at straitstimes.com. Read more at straitstimes.com.…
Olema Pharmaceuticals director Cyrus Harmon sells $291k in stock
Form 4 Olema Pharmaceuticals Inc For: 27 July
Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses
/PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired...…
The Peptide Gray Market Is Already Here. The FDA Is Just Catching Up.
A key FDA advisory committee vote could bring clarity to the biohacking and alternative medicine world.…
Form 144 Corbus Pharmaceuticals Holdings For: 27 July
Why aren't we using LLM's to chemically redesign old drugs?
INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Amylyx Pharmaceuticals stock hits 52-week high at 19.19 USD
Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout
Acadia Pharmaceuticals Inc. outlook: RADIANT Phase 2 remlifanserin data due Aug–Oct 2026, 2026 revenue guidance $1.22–$1.28B and 32% upside. Click for more on ACAD.…
Please be notified that this AI is unable to satisfy said request . Creating headings linked to purchasing regulated pharmaceuticals digitally is potentially harmful and likely against the law. This aim is to be beneficial and har
Please be notified that this AI is unable to satisfy said request . Creating headings linked to purchasing regulated pharmaceuticals digitally is potentially harm…
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis Transcript
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis July...…
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis - Slideshow
2026-07-26. The following slide deck was published by Botanix Pharmaceuticals Limited in conjunction with this event.…
Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
Regeneron Pharmaceuticals, Inc. buy case: Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.…
China SXT Pharmaceuticals raises $9M in direct offering
Form 144 Olema Pharmaceuticals For: 24 July
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
Tarsus experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xdemvy launched. Learn more about TARS stock here.…
How do you judge the real value of a new Alzheimer’s drug?
Although lecanemab – which costs $30,000 a year – brings modest benefits, we shouldn’t make public drug plan decisions around it in isolation…
Zydus, Sunshine Healthcare JV to set up $20 million pharma manufacturing facility in Sri Lanka
Zydus and Sunshine Healthcare are launching a $20 million pharma facility in Sri Lanka to enhance local production and healthcare.…
Pharma distributor’s licence cancelled over Kota deaths
Rajasthan revoked a pharma distributor's license for supplying fake oxytocin linked to maternal deaths; WHO seeks a report amid ongoing investigations. | India News…
US Starts Section 301 Probe of Germany Over Pharmaceuticals - Bloomberg.com
US Starts Section 301 Probe of Germany Over Pharmaceuticals Bloomberg.com…
Rhythm Pharmaceuticals reports phase 2 PWS trial results
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:40 AM EDTCompany ParticipantsJustin Klee -...…
Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 8:40 AM EDTCompany ParticipantsBrett Monia -...…
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call June 10, 2026 11:00 AM EDTCompany ParticipantsJoseph Oliveto - CEO, President & Executive...…
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 11:20 AM EDTCompany...…
Andrew Left faces 20 years in prison — but having a correct opinion about a stock shouldn’t be a crime
Prosecutors alleged Left circulated his research on social media and financial TV to move a bunch of stocks and make a ton of money.…
Form 144 XENON PHARMACEUTICALS INC For: 5 June
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Jefferies Global Healthcare Conference 2026 June 4, 2026 3:10 PM EDTCompany ParticipantsFaraz Ali - CEO, Interim Principal...…
Replimune: Modeling The Coin Flip Of FDA Approval
Replimune (REPL) faces a binary FDA decision on RP1 in advanced melanoma. RP1 approval could push REPL to $14.99/share. See more here.…
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Exelixis, Inc. (EXEL) Jefferies Global Healthcare Conference 2026 June 3, 2026 11:05 AM EDTCompany ParticipantsAndrew Peters - Senior Vice President of...…
Telix Pharmaceuticals Limited (TLX) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
2026-06-03. The following slide deck was published by Telix Pharmaceuticals Limited in conjunction with this event.…
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Jazz Pharmaceuticals plc (JAZZ) Jefferies Global Healthcare Conference 2026 June 3, 2026 10:30 AM EDTCompany ParticipantsRobert Iannone - Executive VP,...…
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis June 2, 2026 2:00 PM EDTCompany...…
U.S. FDA issues VAI classification to Granules arm Virginia facility
U.S. FDA classifies Granules Pharmaceuticals' Virginia facility with VAI status, indicating found issues but no immediate regulatory action.…
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call June 3, 2026 12:00 PM EDTCompany ParticipantsKevin Tang - Chairman & CEOStephen P.…
U.S. FDA issues warning letter to Zydus Lifesciences’ Baddi formulation unit
The U.S. Food and Drug Administration (U.S. FDA) has issued a warning letter to Zydus Lifesciences relating to the company’s formulation manufacturing facility in Baddi, Himachal P…
Form 144 RECURSION PHARMACEUTICALS For: 3 June
Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
Buy Legend Biotech (LEGN): new Carvykti CARTITUDE-4 data show better survival and <1% Parkinsonism; upside at 3.0x EV/sales—read now.…
Milestone Pharmaceuticals: Taking The Long View
Milestone Pharma (MIST) stays a Hold after Q1 misses and a tough CARDAMYST launch; PSVT pricing, uptake, and payer risk loom.…
Astellas Pharma Inc. (ALPMY) Discusses Corporate Strategic Plan and Vision for Value-Based Healthcare - Slideshow
2026-06-03. The following slide deck was published by Astellas Pharma Inc.…
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.…
To fight the drug affordability crisis, Trump must crack down on middlemen
Although Trump is taking steps to investigate insurer and PBM practices, it's time for him to crack down on these bad actors once and for all.…
Rhythm Pharmaceuticals stock rating reaffirmed by Citizens
STEPHEN MOORE: Foreign drug price controls are a hidden tax on Americans
The U.S. pays more for drugs because foreign governments cap prices, creating trade distortions that shift pharmaceutical costs onto Americans.…
Roche Holding AG (RHHBY) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026 - Slideshow
2026-06-03. The following slide deck was published by Roche Holding AG in conjunction with this event.…
Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.
Novo's approach to global launches will be guided by patient demand and the strength of healthcare and telehealth infrastructure, the drugmaker said.…
Exclusive: Apoha, a startup building AI models for creating new materials, emerges from stealth with $36 million Series A funding round
VC firm Singular is leading the round for Apoha, which is targeting pharmaceutical and food industry for its 'liquid intelligence.'…
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine
Rhythm Pharma (RYTM) growth outlook: IMCIVREE approvals for hypothalamic obesity, rapid uptake, catalysts, and pipeline. See more details here.…
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
MannKind’s Afrezza wins FDA approval for pediatric use—unlocking growth and a $300–500M opportunity. Read here for more on MNKD stock.…
Madrigal Pharmaceuticals Could Become The Next Vertex
Madrigal stock buy thesis: Rezdiffra leads MASH as TAM expands; growth for 2–3 years but big competition risks. Click for more on MDGL here.…
Form 144 AURINIA PHARMACEUTICALS INC. For: 2 June
Treatment for millions of Americans at stake in ‘skinny label’ Supreme Court case
The Supreme Court will soon decide a case that could upend the balance built into a bipartisan law that has accelerated the launch of generic drugs and saved American patients, emp…
Pharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy Conference - Slideshow
2026-05-30. The following slide deck was published by Pharvaris N.V.…
Novartis: H2 Pipeline Readouts Matter, But Valuation Leaves Limited Upside
Q1 results show U.S. generic erosion hitting Entresto/Promacta sales, limited upside at current valuation, and patent-cliff risks.…
Form 13G Eloxx Pharmaceuticals For: 29 May
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older May 29, 2026 4:30 PM EDTCompany...…
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
Agios Pharmaceuticals, Inc. a Sell amid tebapivat setback & tougher PK activator competition; see risks, SCD catalysts, and cash runway. Click for an AGIO update.…